Business Description
iX Biopharma Ltd
ISIN : SG1BD9000009
Total Employee Number:
51Compare
Compare
Traded in other countries / regions
42C.Singapore IPO Date
2015-07-22Description
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.8 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -2.99 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 29.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -22 | |||||
3-Year EBITDA Growth Rate | -35.7 | |||||
3-Year EPS without NRI Growth Rate | -58.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.27 | |||||
9-Day RSI | 82.01 | |||||
14-Day RSI | 76.61 | |||||
3-1 Month Momentum % | -8.54 | |||||
6-1 Month Momentum % | 96.34 | |||||
12-1 Month Momentum % | 1873.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.31 | |||||
Quick Ratio | 2.19 | |||||
Cash Ratio | 1.91 | |||||
Days Inventory | 134.77 | |||||
Days Sales Outstanding | 140.37 | |||||
Days Payable | 464.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -0.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 34.48 | |||||
Operating Margin % | -75.93 | |||||
Net Margin % | -68.32 | |||||
EBITDA Margin % | -51.57 | |||||
FCF Margin % | -103.48 | |||||
OCF Margin % | -98.22 | |||||
ROE % | -36.47 | |||||
ROA % | -14.38 | |||||
ROIC % | -23.64 | |||||
3-Year ROIIC % | 214.17 | |||||
ROC (Joel Greenblatt) % | -33.67 | |||||
ROCE % | -24.27 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 110 | |||||
PB Ratio | 34.38 | |||||
Price-to-Tangible-Book | 27.5 | |||||
EV-to-EBIT | -252.02 | |||||
EV-to-EBITDA | -299.41 | |||||
EV-to-Forward-EBITDA | 18.29 | |||||
EV-to-Revenue | 154.4 | |||||
EV-to-Forward-Revenue | 39.43 | |||||
EV-to-FCF | -149.21 | |||||
Price-to-GF-Value | 18.33 | |||||
| Price-to-Net-Current-Asset-Value | 55 | |||||
| Price-to-Net-Cash | 55 | |||||
Earnings Yield (Greenblatt) % | -0.4 | |||||
FCF Yield % | -0.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
iX Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil S$) | 3.826 | ||
| EPS (TTM) (S$) | -0.003 | ||
| Beta | 2.8189 | ||
| 3-Year Sharpe Ratio | 0.9 | ||
| 3-Year Sortino Ratio | 4.41 | ||
| Volatility % | 201.22 | ||
| 14-Day RSI | 76.61 | ||
| 14-Day ATR (S$) | 0.035298 | ||
| 20-Day SMA (S$) | 0.43675 | ||
| 12-1 Month Momentum % | 1873.68 | ||
| 52-Week Range (S$) | 0.018 - 0.585 | ||
| Shares Outstanding (Mil) | 1,093.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
iX Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
iX Biopharma Ltd Stock Events
| Event | Date | Price (S$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-23 10:00 | In 79 days | ||
| Annual report for 2026 | 2026-10-08 | In 63 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 22 days | ||
| Third quarter earnings results for 2026 | 2026-05-08 | 0.41 (+1.23%) | ||
| Second quarter earnings results for 2026 | 2026-02-09 | 0.20 (+2.56%) | ||
| General meeting for 2025 | 2025-10-24 10:00 | 0.09 (+0.00%) | ||
| Annual report for 2025 | 2025-10-08 | 0.04 (-2.38%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 0.02 (+5.00%) | ||
| Second quarter earnings results for 2025 | 2025-02-07 | 0.02 (+4.55%) | ||
| General meeting for 2024 | 2024-10-17 10:00 | 0.03 (+4.00%) |
Show
Entries
iX Biopharma Ltd Frequently Asked Questions
What is iX Biopharma Ltd(SGX:42C)'s stock price today?
The current price of SGX:42C is S$0.55. The 52 week high of SGX:42C is S$0.59 and 52 week low is S$0.02.
When is next earnings date of iX Biopharma Ltd(SGX:42C)?
The next earnings date of iX Biopharma Ltd(SGX:42C) is 2026-08-28 Est..
Does iX Biopharma Ltd(SGX:42C) pay dividends? If so, how much?
iX Biopharma Ltd(SGX:42C) does not pay dividend.
Press Release
Articles on iX Biopharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers